LONG TERM CARE
With an aging population, the focus on controlling costs and improving quality in long term care becomes paramount, with increasing evidence and data pointing to the benefits of personalized medicine.
Long-term care facilities provide an ideal environment for contracting and facilitating the spread of infection, and antibiotic resistance has become a public health crisis.
Respiratory infections can spread quickly among residents, particularly the immunocompromised and those with comorbidities. More than 1 in 10 nursing home residents have a pressure ulcer. Of the 11% of nursing home residents on antibiotics on any given day, one-third of antibiotic prescriptions are for UTI, yet half are for the wrong drug, dose or duration. Delayed diagnosis and treatment for these respiratory, wound and urinary tract infections can lead to increased morbidity, mortality and healthcare costs.
Further, there are patients every day who contract infections that cannot be treated with currently available antibiotics. Each year in the US, at least 2 million people acquire infections with bacteria resistant to one-or-more of the antibiotics designed to treat them, and at least 23,000 people die as a direct result. The medical cost per patient with an antibiotic-resistant infection is estimated to range from $18-30k.
Polypharmacy and adverse drug events are the 4th leading cause of death.
Precision medicine solutions from Attis Healthcare enable providers to personalize care in long term care facilities.
Onsite PCR Syndromic Testing
Conventional culture testing can take several days to weeks to result and is limited to the detection of single pathogens, often impeding the effective identification and treatment of infection.
Advanced Real Time-PCR technology allows for the most rapid pathogen identification, quantification and detection of antibiotic resistance. Collected via non-invasive swab, PCR detects multiple pathogens at once, results in 12-24 hours and is 3-5x more sensitive than standard culture. In addition, PCR testing identifies the pathogen load and genetic variations that allow pathogens to become resistant to antibiotic. This is instrumental when selecting an effective antibiotic regimen for the patient and reducing unnecessary antibiotic use.
Our proprietary, turnkey tabletop solution runs 2-4 tests per hour and enables a provider to offer comprehensive, highly sensitive and accurate PCR diagnostic testing onsite. The facility can bill and collect for the test, increasing revenue while improving patient care and outcomes.
PCR Molecular Pathogen identification is available in long term care facilities for the detection of respiratory, urinary tract, wound and vaginitis/STI infections, with antibiotic resistance detection for UTI and wound panels.
Negative Pressure Wound Therapy (NPWT)
With recent changes to Medicare laws, nursing homes are now incentivized through higher reimbursements to accept patients with higher acuity levels, including those with acute wounds. Facilities have the opportunity to prevent hospital re-admissions by healing and/or effectively managing existing community-acquired pressure ulcers, chronic wounds, and surgical incisions.
Negative pressure wound therapy promotes wound healing and closure by reducing the risk of infection, increasing blood flow to the wound area and removing excess fluids that can hamper the success of the treatment. But not all NPWT is equally effective. Wound etiology, patient pain threshold and the benefits of variable pressure or lower negative pressure for different types of tissue, can affect outcomes.
Our Prospera PRO series of negative pressure wound therapy systems are clinically superior, providing ease of use and flexibility for both patients and clinicians. By implementing Attis' NPWT solution, long term care facilities can provide leading-edge therapy and better position themselves to accept higher acuity patients and reap the benefits of higher reimbursements.
Pharmacogenetics (PGx) and Medication Therapy Management
Pharmacogenetics is testing for genetic differences which can affect individual responses to drugs, in terms of both therapeutic and adverse effects. By personalizing a patient’s care plan using these unique genetic characteristics, PGx and Medication Therapy Management can lead to reduced trial-and-error prescriptions, decreased time to symptom relief, significant drug and healthcare savings and improved quality of life.
The PGx test is a simple cheek swab that is run once and can be used for life. A genetic response report is then generated combining genetic markers, molecular data and clinical evidence. This is where Attis’ solution takes it a step further. While PGx results once could be hard to digest and interpret, we offer an interactive medication management tool allowing the healthcare provider to "play" with alternative drug options to assess how the new therapy would affect drug-gene and drug-drug interactions, and find the scenario that presents the least amount of risk. Powered by genomic data from the Coriell Institute of Medical Research, this tool factors in genetics, demographics and lifestyle factors to help the healthcare provider make scientifically-based treatment decisions.